{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:54:35Z","timestamp":1787054075084,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In 2016, Methylation-Specific Quantitative Melt Analysis (MS-QMA) on 3,340 male probands increased diagnostic yield from 1.60% to 1.84% for fragile X syndrome (FXS) using a pooling approach. In this study probands from Lineagen (UT, U.S.A.) of both sexes were screened using MS-QMA without sample pooling. The cohorts included: (i) 279 probands with no FXS full mutation (FM: CGG\u2009&gt;\u2009200) detected by AmplideX CGG sizing; (ii) 374 negative and 47 positive controls. MS-QMA sensitivity and specificity in controls approached 100% for both sexes. For male probands with no FM detected by standard testing (n\u2009=\u2009189), MS-QMA identified abnormal DNA methylation (mDNA) in 4% normal size (NS:\u2009&lt;\u200944 CGGs), 6% grey zone (CGG 45\u201354) and 12% premutation (CGG 54\u2013199) alleles. The abnormal mDNA was confirmed by AmplideX methylation sensitive (m)PCR and EpiTYPER tests. In contrast, no abnormal mDNA was detected in 89 males with NS alleles from the general population. For females, 11% of 43 probands with NS alleles by the AmplideX sizing assay had abnormal mDNA by MS-QMA, with FM \/ NS mosaicism confirmed by AmplideX mPCR. <jats:italic>FMR1<\/jats:italic> MS-QMA analysis can cost-effectively screen probands of both sexes for methylation and FM mosaicism that may be missed by standard testing.<\/jats:p>","DOI":"10.1038\/s41598-019-51618-7","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T18:34:30Z","timestamp":1572028470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Abnormally Methylated FMR1 in Absence of a Detectable Full Mutation in a U.S.A Patient Cohort Referred for Fragile X Testing"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-1807","authenticated-orcid":false,"given":"Charles H.","family":"Hensel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena J.","family":"Vanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange M.","family":"Aliaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Twede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon W.","family":"Morison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Amor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Godler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"51618_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature14135","volume":"519","author":"Deciphering Developmental Disorders Study","year":"2015","unstructured":"Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 519, 223\u20138 (2015).","journal-title":"Nature"},{"key":"51618_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3109\/13668250.2011.648609","volume":"37","author":"CM Doran","year":"2012","unstructured":"Doran, C. M. et al. How much does intellectual disability really cost? First estimates for Australia. J Intellect Dev Disabil 37, 42\u20139 (2012).","journal-title":"J Intellect Dev Disabil"},{"key":"51618_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ajhg.2017.07.016","volume":"101","author":"DR Krupp","year":"2017","unstructured":"Krupp, D. R. et al. Exonic Mosaic Mutations Contribute Risk for Autism Spectrum Disorder. Am J Hum Genet 101, 369\u2013390 (2017).","journal-title":"Am J Hum Genet"},{"key":"51618_CR4","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/hmg\/ddq037","volume":"19","author":"DE Godler","year":"2010","unstructured":"Godler, D. E. et al. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Human molecular genetics 19, 1618\u201332 (2010).","journal-title":"Human molecular genetics"},{"key":"51618_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1542\/peds.2008-0317","volume":"123","author":"RJ Hagerman","year":"2009","unstructured":"Hagerman, R. J. et al. Advances in the treatment of fragile X syndrome. Pediatrics 123, 378\u201390 (2009).","journal-title":"Pediatrics"},{"key":"51618_CR6","doi-asserted-by":"publisher","first-page":"7366","DOI":"10.1007\/s12035-018-0922-2","volume":"55","author":"C Salvoro","year":"2018","unstructured":"Salvoro, C. et al. Rare Risk Variants Identification by Identity-by-Descent Mapping and Whole-Exome Sequencing Implicates Neuronal Development Pathways in Schizophrenia and Bipolar Disorder. Mol Neurobiol 55, 7366\u20137376 (2018).","journal-title":"Mol Neurobiol"},{"key":"51618_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cels.2015.11.002","volume":"1","author":"J Li","year":"2015","unstructured":"Li, J. et al. Identification of Human Neuronal Protein Complexes Reveals Biochemical Activities and Convergent Mechanisms of Action in Autism Spectrum Disorders. Cell Syst 1, 361\u2013374 (2015).","journal-title":"Cell Syst"},{"key":"51618_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/gim.2018.52","volume":"20","author":"CM Kraan","year":"2018","unstructured":"Kraan, C. M. et al. FMR1 allele size distribution in 35,000 males and females: a comparison of developmental delay and general population cohorts. Genet Med 20, 1627\u20131634 (2018).","journal-title":"Genet Med"},{"key":"51618_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1373\/clinchem.2015.244681","volume":"62","author":"SM Aliaga","year":"2016","unstructured":"Aliaga, S. M. et al. Identification of Males with Cryptic Fragile X Alleles by Methylation-Specific Quantitative Melt Analysis. Clin Chem 62, 343\u201352 (2016).","journal-title":"Clin Chem"},{"key":"51618_CR10","first-page":"290","volume":"15","author":"Y Inaba","year":"2014","unstructured":"Inaba, Y. et al. Early Detection of Fragile X Syndrome: Applications of a Novel Approach for Improved Quantitative Methylation Analysis in Venous Blood and Newborn Blood Spots. Clin Chem 15, 290\u20138 (2014).","journal-title":"Clin Chem"},{"key":"51618_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dmcn.13985","volume":"61","author":"CM Kraan","year":"2018","unstructured":"Kraan, C. M., Godler, D. E. & Amor, D. J. Epigenetics of fragile X syndrome and fragile X-related disorders. Dev Med Child Neurol 61, 121\u2013127 (2018).","journal-title":"Dev Med Child Neurol"},{"key":"51618_CR12","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1017\/erm.2015.11","volume":"17","author":"DE Godler","year":"2015","unstructured":"Godler, D. E. et al. Detection of skewed X-chromosome inactivation in Fragile X syndrome and X chromosome aneuploidy using quantitative melt analysis. Expert Rev Mol Med 17, e13 (2015).","journal-title":"Expert Rev Mol Med"},{"key":"51618_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21990-x","volume":"8","author":"M Arpone","year":"2018","unstructured":"Arpone, M. et al. Intragenic DNA methylation in buccal epithelial cells and intellectual functioning in a paediatric cohort of males with fragile X. Scientific Reports 8, 3644 (2018).","journal-title":"Scientific Reports"},{"key":"51618_CR14","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1002\/ajmg.a.37954","volume":"170","author":"TY Hwang","year":"2016","unstructured":"Hwang, T. Y. et al. Partially Methylated Alleles, Microdeletion and Tissue Mosaicism in a Fragile X Male with Tremor and Ataxia at 30 Years of Age: A Case Report. Am J Med Genet A. 170, 3327\u20133332 (2016).","journal-title":"Am J Med Genet A."},{"key":"51618_CR15","doi-asserted-by":"publisher","first-page":"pii: E68","DOI":"10.3390\/genes7090068","volume":"7","author":"YT Hwang","year":"2016","unstructured":"Hwang, Y. T. et al. Molecular Inconsistencies in a Fragile X Male with Early Onset Ataxia. Genes (Basel) 7, pii: E68 (2016).","journal-title":"Genes (Basel)"},{"key":"51618_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1212\/WNL.0000000000001496","volume":"84","author":"KM Cornish","year":"2015","unstructured":"Cornish, K. M. et al. Novel methylation markers of the dysexecutive-psychiatric phenotype in FMR1 premutation women. Neurology 84, 1631\u20138 (2015).","journal-title":"Neurology"},{"key":"51618_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1373\/clinchem.2011.177626","volume":"58","author":"DE Godler","year":"2012","unstructured":"Godler, D. E. et al. Fragile X mental retardation 1 (FMR1) intron 1 methylation in blood predicts verbal cognitive impairment in female carriers of expanded FMR1 alleles: evidence from a pilot study. Clinical chemistry 58, 590\u20138 (2012).","journal-title":"Clinical chemistry"},{"key":"51618_CR18","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/hmg\/ddt002","volume":"22","author":"DE Godler","year":"2013","unstructured":"Godler, D. E. et al. Relationships between age and epi-genotype of the FMR1 exon 1\/intron 1 boundary are consistent with non-random X-chromosome inactivation in FM individuals, with the selection for the unmethylated state being most significant between birth and puberty. Hum Mol Genet 22, 1516\u201324 (2013).","journal-title":"Hum Mol Genet"},{"key":"51618_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ejhg.2016.204","volume":"25","author":"A Quartier","year":"2017","unstructured":"Quartier, A. et al. Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome. Eur J Hum Genet 25, 423\u2013431 (2017).","journal-title":"Eur J Hum Genet"},{"key":"51618_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1755-8166-1-5","volume":"1","author":"MS Khaniani","year":"2008","unstructured":"Khaniani, M. S., Kalitsis, P., Burgess, T. & Slater, H. R. An improved Diagnostic PCR Assay for identification of Cryptic Heterozygosity for CGG Triplet Repeat Alleles in the Fragile X Gene (FMR1). Mol Cytogenet 1, 5 (2008).","journal-title":"Mol Cytogenet"},{"key":"51618_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/00066982-200005030-00008","volume":"5","author":"D Francis","year":"2000","unstructured":"Francis, D., Burgess, T., Mitchell, J. & Slater, H. Identification of small FRAXA premutations. Mol Diagn 5, 221\u20135 (2000).","journal-title":"Mol Diagn"},{"key":"51618_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2353\/jmoldx.2008.070073","volume":"10","author":"F Tassone","year":"2008","unstructured":"Tassone, F., Pan, R., Amiri, K., Taylor, A. K. & Hagerman, P. J. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn 10, 43\u20139 (2008).","journal-title":"J Mol Diagn"},{"key":"51618_CR23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/0092-8674(91)90283-5","volume":"67","author":"YH Fu","year":"1991","unstructured":"Fu, Y. H. et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67, 1047\u201358 (1991).","journal-title":"Cell"},{"key":"51618_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/GIM.0b013e3181d0d40e","volume":"12","author":"FM Hantash","year":"2010","unstructured":"Hantash, F. M. et al. Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening. Genet Med 12, 162\u201373 (2010).","journal-title":"Genet Med"},{"key":"51618_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/gim.2012.134","volume":"15","author":"Y Inaba","year":"2013","unstructured":"Inaba, Y. et al. Fragile X-related element 2 methylation analysis may provide a suitable option for inclusion of fragile X syndrome and\/or sex chromosome aneuploidy into newborn screening: a technical validation study. Genet Med 15, 290\u20138 (2013).","journal-title":"Genet Med"},{"key":"51618_CR26","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1373\/clinchem.2011.177626","volume":"58","author":"DE Godler","year":"2012","unstructured":"Godler, D. E. et al. Fragile X Mental Retardation 1 (FMR1) Intron 1 Methylation in Blood Predicts Verbal Cognitive Impairment in Female Carriers of Expanded FMR1 Alleles: Evidence from a Pilot Study. Clin Chem 58, 590\u20138 (2012).","journal-title":"Clin Chem"},{"key":"51618_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/GIM.0b013e31820a780f","volume":"13","author":"L Chen","year":"2011","unstructured":"Chen, L. et al. High-resolution methylation polymerase chain reaction for fragile X analysis: evidence for novel FMR1 methylation patterns undetected in Southern blot analyses. Genet Med 13, 528\u201338 (2011).","journal-title":"Genet Med"},{"issue":"12","key":"51618_CR28","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/ijms17122070","volume":"17","author":"Karen Ho","year":"2016","unstructured":"Ho, K. S. et al. Chromosomal Microarray Analysis of Consecutive Individuals with Autism Spectrum Disorders Using an Ultra-High Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders. Int J Mol Sci 17 (2016).","journal-title":"International Journal of Molecular Sciences"},{"key":"51618_CR29","doi-asserted-by":"crossref","unstructured":"Hensel, C. et al. Analytical and Clinical Validity Study of FirstStepDx PLUS: A Chromosomal Microarray Optimized for Patients with Neurodevelopmental Conditions. PLoS Curr 9 (2017).","DOI":"10.1371\/currents.eogt.7d92ce775800ef3fbc72e3840fb1bc22"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51618-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:58:28Z","timestamp":1671289108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51618"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51618-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"28 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"David Eugeny Godler is named as an inventor on patent applications [PCT\/AU2010\/000169, PCT\/AU2011\/001024 and PCT\/AU2014\/000044] related to the technology described in this article. Lineagen Inc. currently utilizes AmplideX PCR (Asuragen) and AmplideX mPCR (Asuragen) as a commercial genetic testing offering. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15315"}}